UNOFFICIAL COPY 25 RS BR 951
Page 1 of 2
XXXX 2/19/2025 9:52 AM Jacketed
AN ACT relating to buprenorphine products. 1
Be it enacted by the General Assembly of the Commonwealth of Kentucky: 2
SECTION 1. A NEW SECTION OF KRS CHAPTER 311 IS CREATED TO 3
READ AS FOLLOWS: 4
(1) Notwithstanding any law to the contrary, a physician who is licensed in Kentucky 5
and meets the qualifications to prescribe, dispense, or administer Buprenorphine-6
Mono-Product or Buprenorphine-Combined-with-Naloxone shall use 7
professional judgement to prescribe, dispense, or administer a specific dosage 8
regimen of Buprenorphine-Mono-Product or Buprenorphine-Combined-with-9
Naloxone that best meets the treatment needs of a patient. 10
(2) The Kentucky Board of Medical Licensure shall not suspend, limit, or restrict a 11
license or take other disciplinary action against a physician who prescribes, 12
dispenses, or administers Buprenorphine-Mono-Product or Buprenorphine-13
Combined-with-Naloxone to a patient in accordance with subsection (1) of this 14
section. 15
(3) The board shall promulgate administrative regulations in accordance with KRS 16
Chapter 13A to implement the requirements of this section. 17
SECTION 2. A NEW SECTION OF KRS CHAPTER 314 IS CREATED TO 18
READ AS FOLLOWS: 19
(1) Notwithstanding any law to the contrary, an advanced practice registered nurse 20
who is licensed in Kentucky and meets the qualifications to prescribe, dispense, 21
or administer Buprenorphine-Mono-Product or Buprenorphine-Combined-with-22
Naloxone shall use professional judgement to prescribe, dispense, or administer a 23
specific dosage regimen of Buprenorphine-Mono-Product or Buprenorphine-24
Combined-with-Naloxone that best meets the treatment needs of a patient. 25
(2) The board shall not suspend, limit, or restrict a license or take other disciplinary 26
action against an advanced practice registered nurse who prescribes, dispenses, 27 UNOFFICIAL COPY 25 RS BR 951
Page 2 of 2
XXXX 2/19/2025 9:52 AM Jacketed
or administers Buprenorphine-Mono-Product or Buprenorphine-Combined-with-1
Naloxone to a patient in accordance with subsection (1) of this section. 2
(3) The board shall promulgate administrative regulations in accordance with KRS 3
Chapter 13A to implement the requirements of this section. 4